Overexpression of the Catalytic Subunit of Protein Phosphatase 2A Impairs Cardiac Function
Overview
Authors
Affiliations
Reversible protein phosphorylation is an essential regulatory mechanism in many cellular functions. In contrast to protein kinases, the role and regulation of protein phosphatases has remained ambiguous. To address this issue, we generated transgenic mice that overexpress the catalytic subunit alpha of protein phosphatase 2A (PP2A) (PP2Acalpha) in the heart driven by the alpha-myosin heavy chain promoter. Overexpression of the PP2Acalpha gene in the heart led to increased levels of the transgene both at RNA and protein levels. This was accompanied by a significant increase of PP2A enzyme activity in the myocardium. Morphological analysis revealed isles of necrosis and fibrosis. The phosphorylation state of phospholamban, troponin inhibitor, and eukaryotic elongation factor 2 was reduced significantly. The expression of junctional (calsequestrin) and free SR proteins (SERCA and phospholamban) was not altered. Whereas no increase in morbidity or mortality was noted, transgenic mice developed cardiac hypertrophy and reduced contractility of the heart, as well as cardiac dilatation as shown by biplane echocardiography. Taken together, these findings are indicative of the fundamental role of PP2A in cardiac function and imply that disturbances in protein phosphatases expression and activity may cause or aggravate the course of cardiac diseases.
Yang N, Hou Y, Cui T, Yu J, He S, Zhu H Int J Nanomedicine. 2024; 19:9035-9053.
PMID: 39253060 PMC: 11381219. DOI: 10.2147/IJN.S463477.
Contractile effects of stimulation of D-dopamine receptors in the isolated human atrium.
Gergs U, Pham T, Rayo Abella L, Hesse C, Grundig P, Dhein S Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1497-1508.
PMID: 39102031 PMC: 11825631. DOI: 10.1007/s00210-024-03340-z.
Gergs U, Wackerhagen S, Fuhrmann T, Schafer I, Neumann J Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):5731-5743.
PMID: 38308688 PMC: 11329414. DOI: 10.1007/s00210-024-02973-4.
Rayo Abella L, Jacob H, Hesse C, Hofmann B, Schneider S, Schindler L Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):4939-4959.
PMID: 38177456 PMC: 11166794. DOI: 10.1007/s00210-023-02901-y.
Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.
Yu H, Zaveri S, Sattar Z, Schaible M, Perez Gandara B, Uddin A Medicina (Kaunas). 2023; 59(9).
PMID: 37763671 PMC: 10535831. DOI: 10.3390/medicina59091552.